Spero Therapeutics Inc ($SPRO) recently announced a significant $105 million non-dilutive, non-recourse royalty financing deal with Healthcare Royalty affiliates, majority owned by KKR. This financing, backed by future milestone and royalty payments from Utebzi — the first oral carbapenem antibiotic approved by the FDA for complicated urinary tract infections — extends Spero’s cash runway into the second half of 2029. The company will repay the financing through quarterly payments sourced exclusively from royalties paid by GSK, which holds exclusive rights to develop and commercialize Utebzi globally, excluding select Asian markets.
Read More about Biotech & Pharmaceutical Stocks
Latest Updates on Biotech & Pharmaceutical Stocks
Alongside this financing, Spero secured exclusive worldwide rights (outside Greater China) to SP001, a third-generation anti-CD40L monoclonal antibody licensed from Innovent Biologics, targeting immune-mediated diseases such as IgG4-related disease. The company plans to initiate a Phase II trial for SP001 in mid-2027, aiming to enroll patients in an open-label study with two dosing arms. To strengthen clinical leadership, Spero appointed Debra Jeske Zack as Chief Medical Officer, bringing over 25 years of experience in immune disease therapies. These strategic moves position Spero to advance its immunology pipeline while maintaining financial stability well into 2029.
Did you know?
Royalty financing allows biotech companies like Spero to raise capital without diluting shareholder equity, by leveraging future royalty streams from approved drugs. This approach helps fund ongoing research while preserving ownership stakes.
Disclaimer
This content is for entertainment and discussion purposes only. It is based on publicly available headlines and social media commentary, which can be messy and ever-evolving. We are not financial advisors, and this is not investment advice. The publisher may hold positions in securities mentioned. We aim to keep things accurate—if you catch something off, please let us know.
Powered by - Trading Watch Premium
This data is 100% free and is made possible by our Monthly Supporters.
No Comments